VRDN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Viridian Therapeutics Inc (VRDN) is not a strong buy at this moment for a beginner investor with a long-term strategy. The stock lacks immediate positive trading signals, has bearish technical indicators, and faces competitive challenges in its market. While the company's financials show growth in revenue and improved net income, the overall sentiment from analysts and the market remains cautious. It is advisable to hold off on investing until clearer positive catalysts emerge.
The technical indicators for VRDN are bearish. The MACD histogram is negative (-0.251) and contracting, the RSI_6 is at 25.286 (neutral zone), and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level (15.893), with key support at 13.633 and resistance at 18.152.
The company announced a partnership with Outside the Box Capital, which could enhance market services and visibility. Financials show an 83.33% YoY revenue increase and improved net income and EPS.
Analysts have lowered price targets across the board due to competitive pressures from Amgen's Tepezza and concerns about Viridian's lead asset in thyroid eye disease. The stock has been removed from Wedbush's Best Ideas List, and the market reaction to recent clinical trial results has been negative.
In Q4 2025, revenue increased by 83.33% YoY to $132,000. Net income improved by 50.96% YoY to -$120,355,000, and EPS increased by 28.28% YoY to -1.27. Gross margin remained stable at 100%.
Analysts maintain an Outperform or Buy rating but have significantly lowered price targets (e.g., Evercore ISI: $24 from $32, Truist: $36 from $40, Wedbush: $31 from $37). Concerns about competitive dynamics and clinical trial results are driving the cautious sentiment.
